S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
NASDAQ:SRRA

Sierra Oncology (SRRA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$54.99
$54.99
50-Day Range
$54.73
$54.99
52-Week Range
$14.91
$55.19
Volume
N/A
Average Volume
931,731 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SRRA stock logo

About Sierra Oncology Stock (NASDAQ:SRRA)

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.


SRRA Stock News Headlines

Sierra Oncology Inc.
Sierra Coupon for October
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Sierra Oncology (NASDAQ: SRRA)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Sierra Leone
Interventional Oncology Global Market - Forecast To 2029
Sierra Oncology hits 52w high – but will it continue?
Analyst Ratings for Sierra Oncology
See More Headlines
Receive SRRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2021
Today
3/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Fax
N/A
Employees
109
Year Founded
N/A

Profitability

Net Income
$-94,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$6.16 per share

Miscellaneous

Free Float
13,650,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.03
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Stephen George Dilly M.B.B.S (Age 62)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Sukhi Jagpal CPA (Age 48)
    CA, CBV, CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $648.02k
  • Dr. Barbara J. Klencke M.D. (Age 65)
    Chief Medical Officer
    Comp: $773.39k
  • Ms. Christina Thomson J.D. (Age 51)
    M.S., Gen. Counsel, Chief Compliance Officer & Sec.
  • Mr. William D. TurnerMr. William D. Turner (Age 56)
    Chief Regulatory & Technical Operations Officer
  • Mr. Kevin Norrett M.B.A. (Age 49)
    M.S., Chief Bus. Officer














SRRA Stock Analysis - Frequently Asked Questions

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.78) by $0.32.

What other stocks do shareholders of Sierra Oncology own?
This page (NASDAQ:SRRA) was last updated on 3/3/2024 by MarketBeat.com Staff